What is Cerebrolysin?
Cerebrolysin is a research preparation made from purified pig brain tissue. It contains a mix of small peptides — think of them as tiny protein fragments — and free amino acids (the building blocks of proteins). Because of its biological origin, it doesn't have a single molecular formula like a simple drug would.
It has been used clinically in Russia, Eastern Europe, China, and other parts of Asia for decades, particularly after strokes and in dementia care.[1] In research contexts, scientists are interested in it mainly for its potential to protect brain cells and support recovery after neurological injury.
Important note: This page is for research and educational purposes only. Cerebrolysin is not approved for use in the United States and this is not medical advice.
How Cerebrolysin Works
Think of your brain cells as office workers under stress — damaged, overloaded, or cut off from supplies after an injury like a stroke. Cerebrolysin's peptides are thought to act like an emergency response team: potentially stabilizing cell membranes, reducing inflammation, and mimicking naturally occurring growth factors that tell nerve cells to survive and repair themselves.
More precisely, the preparation is said to have neurotrophic properties — meaning it may behave similarly to the brain's own nerve growth factors, which normally help neurons stay healthy and form new connections.[2] It is also described as neuroprotective, meaning it may help shield brain cells from the cascade of damage that follows a stroke or traumatic brain injury.[4]
That's the theory. What does the actual research say? Keep reading.
What the Research Shows
Most of the clinical research on Cerebrolysin falls into a few key areas. Here's a plain-language breakdown of what scientists have found so far — and where the evidence is still uncertain.
Acute Ischaemic Stroke
Multiple Cochrane systematic reviews — the gold standard of evidence summaries — have looked at Cerebrolysin for ischaemic stroke (the kind caused by a blood clot blocking a blood vessel in the brain). The most recent, published in 2023 and covering seven randomized controlled trials with 1,773 participants, found that Cerebrolysin probably makes little to no difference in preventing death compared to placebo.[1] An important safety flag emerged: there was a potential increase in non-fatal serious adverse events in the Cerebrolysin groups, especially at the 30 mL for 10 days dosing schedule.[1] Earlier reviews reached similar conclusions.[3][5] The evidence quality was rated as moderate, meaning researchers are fairly — but not completely — confident in these findings.
Vascular Dementia
A 2019 Cochrane review covering six trials and 597 participants found that Cerebrolysin showed a possible benefit for cognition and global function in people with vascular dementia (dementia caused by reduced blood flow to the brain).[2] However, the evidence quality was rated as very low — meaning the results are uncertain and could change significantly with better-designed studies. The reviewers noted that any real-world benefits might be too small to matter clinically, and called for larger, more rigorous trials.[2]
Traumatic Brain Injury (TBI)
A 2023 systematic review and meta-analysis specifically examined Cerebrolysin in patients with traumatic brain injury. Researchers found signals suggesting potential benefit for neurological recovery outcomes, though the authors stressed that the existing trial data had limitations and that more high-quality research is needed before firm conclusions can be drawn.[4]
Subarachnoid Hemorrhage
A 2023 meta-analysis also looked at Cerebrolysin in patients with subarachnoid hemorrhage (bleeding around the brain). Again, some positive signals were observed in neurological outcomes, but the reviewers noted the need for further well-designed trials to confirm any effects.[6]
What Cerebrolysin Is Being Studied For
- Acute ischaemic stroke recovery[1]
- Vascular dementia and cognitive decline[2]
- Traumatic brain injury (TBI)[4]
- Subarachnoid hemorrhage outcomes[6]
- General neuroprotection and neurological repair mechanisms
How Cerebrolysin Is Dosed in Research
Dosing in published clinical trials has varied considerably depending on the condition being studied, the duration of treatment, and the study design. For acute ischaemic stroke, for example, the regimen used in major trials is summarized in the dosage chart on this page — check it for the specific amounts and schedules researchers have used. If you're trying to understand how volumes scale or convert between concentrations, the calculator on this site can help you work through the numbers. Always refer to the original published protocols for full context, since dosing in research is highly specific to the study design and should never be self-administered.
Mixing and Storing Cerebrolysin
In clinical trial settings, Cerebrolysin is supplied as a ready-made solution for intravenous (IV) infusion — it comes pre-dissolved and does not require reconstitution from a powder the way many other research peptides do. The solution is typically diluted into a standard saline bag before slow IV infusion. Storage requirements follow standard pharmaceutical guidelines: keep vials refrigerated, protected from light, and away from freezing temperatures. Once diluted for infusion, the solution should be used promptly and not stored. For any specific handling, always refer to the supplier's documentation and the published trial protocols, as conditions can vary by formulation and source.
Sources
- Cerebrolysin for acute ischaemic stroke. — The Cochrane database of systematic reviews, 2023. PMID 37818733.
- Cerebrolysin for vascular dementia. — The Cochrane database of systematic reviews, 2019. PMID 31710397.
- Cerebrolysin for acute ischaemic stroke. — The Cochrane database of systematic reviews, 2020. PMID 32662068.
- Cerebrolysin in Patients with TBI: Systematic Review and Meta-Analysis. — Brain sciences, 2023. PMID 36979317.
- Cerebrolysin for acute ischaemic stroke. — The Cochrane database of systematic reviews, 2017. PMID 28430363.
- Cerebrolysin in Patients with Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis. — Journal of clinical medicine, 2023. PMID 37892776.
EN
BR
ES
FR